Selank

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics, Russian Academy of Sciences. It was created by extending the naturally occurring immune peptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide sequence, which increases plasma stability and adds anxiolytic/nootropic properties. The name 'Selank' derives from 'SE' (short for 'synthetic analog') and 'LANK' (from tuftsin-related terminology). It has been approved in Russia as an anxiolytic drug since 2009.

Selank and benzodiazepines both reduce anxiety, but through different mechanisms. Benzodiazepines act directly on GABA-A receptors, producing rapid sedation, muscle relaxation, and anxiolysis—but with dose-dependent cognitive impairment, tolerance, dependence, and withdrawal. Selank modulates GABA tone indirectly, inhibits enkephalin-degrading enzymes, and upregulates BDNF. The result is anxiolysis without sedation, without cognitive impairment, and without documented tolerance or withdrawal in research settings. However, Selank's onset is slower and effects more subtle compared to benzodiazepines.

Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen and found on immunoglobulin G. It stimulates phagocytic activity of monocytes, macrophages, and granulocytes. Selank was created by adding Pro-Gly-Pro to tuftsin's C-terminus, which dramatically increases its plasma stability (half-life extended from minutes to hours) and adds anxiolytic and nootropic properties. Selank retains tuftsin's immunomodulatory receptor interactions while gaining new CNS activity.

Yes. Selank has been registered in Russia as an anxiolytic nasal spray (under the trade name 'Selank') for generalized anxiety disorder, neurasthenia, and adjustment disorders with anxiety since 2009. It is also registered in Ukraine. Outside these countries, it is not approved for any clinical use. Western regulatory agencies have not reviewed it. This is one of the few peptides in the world approved specifically as an anti-anxiety drug, giving it a degree of clinical validation not available for most research peptides.

Because Selank retains tuftsin's structural foundation, it maintains tuftsin-receptor interactions on immune cells. Studies show enhanced phagocytic activity in monocytes and macrophages, increased natural killer cell cytotoxicity, and modulation of cytokine production (notably IL-6). Research has documented gene expression changes across 50+ immunity-related genes. These immunomodulatory effects appear independent of the anxiolytic CNS effects and may be relevant for research into immune optimization and infectious disease models.

A 2008 study in Doklady Biological Sciences documented significant upregulation of BDNF mRNA (approximately 30–45%) in rat hippocampus within 24 hours of intranasal Selank administration. NGF and neurotrophin-3 were also elevated. This neurotrophic effect is believed to contribute to Selank's memory-enhancing properties and may explain why its anxiolytic effects improve cognitive performance rather than impairing it (as benzodiazepines do). The BDNF pathway also suggests potential relevance for depression research.

Both are Russian-developed neuropeptides with domestic regulatory approval and overlapping nootropic properties, but different primary profiles. Selank is primarily anxiolytic, with nootropic effects secondary. Semax is primarily nootropic/neuroprotective, with anxiolytic effects less prominent. Both upregulate BDNF. Selank derives from tuftsin (immune peptide); Semax derives from ACTH (hormonal peptide). Researchers sometimes combine them for complementary anxiolytic + cognitive enhancement effects, though no published head-to-head trials compare the two directly.

Russian clinical protocols for Selank use intranasal administration at 250–500 mcg per dose, given 2–3 times daily. A typical treatment course in Russian protocols runs 10–14 days. The intranasal route is preferred because Selank's short systemic half-life means direct CNS delivery via olfactory pathways provides more consistent effects than subcutaneous dosing. No standardized Western clinical protocols exist as Selank has not completed FDA or EMA review.

Russian clinical experience includes co-administration of Selank and Semax, leveraging Selank's anxiolytic profile with Semax's nootropic/neuroprotective effects. Both are administered intranasally and share the Pro-Gly-Pro stabilization motif but act through different primary pathways (tuftsin receptors for Selank, melanocortin/ACTH pathways for Semax). No controlled combination trials have been published in international peer-reviewed literature. The theoretical rationale is that anxiety reduction (Selank) may enhance cognitive performance gains (Semax) by removing stress-related interference.

SSRIs increase serotonin availability by blocking reuptake transporters, requiring 2-6 weeks for full effect and carrying side effects including sexual dysfunction, weight changes, and discontinuation syndrome. Selank acts through a different pathway: inhibiting enkephalin-degrading enzymes (increasing endogenous opioid tone), modulating GABA-A receptor sensitivity, and upregulating BDNF. Effects are reported within 30 minutes of intranasal dosing. Selank does not directly alter serotonin reuptake, though downstream effects on serotonin metabolism have been documented. The key clinical distinction is rapid onset without the delayed efficacy and side effect burden of SSRIs.